• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于预测低级别乳头状尿路上皮癌(LGPUCC)复发风险的表观遗传标志物组合及其在经尿道切除术后使用尿液进行监测的潜在用途。

An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine.

作者信息

Maldonado Leonel, Brait Mariana, Michailidi Christina, Munari Enrico, Driscoll Tina, Schultz Luciana, Bivalacqua Trinity, Schoenberg Mark, Sidransky David, Netto George J, Hoque Mohammad Obaidul

机构信息

Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. These authors contributed equally to this work.

Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

出版信息

Oncotarget. 2014 Jul 30;5(14):5218-33. doi: 10.18632/oncotarget.2129.

DOI:10.18632/oncotarget.2129
PMID:24980822
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4170626/
Abstract

By a candidate gene approach, we analyzed the promoter methylation (PM) of 8 genes genes (ARF, TIMP3, RAR-β2, NID2, CCNA1, AIM1, CALCA and CCND2) by quantitative methylation specific PCR (QMSP) in DNA of 17 non-recurrent and 19 recurrent noninvasive low grade papillary urothelial cell carcinoma (LGPUCC) archival tissues. Among the genes tested, by establishing an empiric cutoff value, CCND2, CCNA1, NID2, and CALCA showed higher frequency of methylation in recurrent than in non-recurrent LGPUCC: CCND2 10/19 (53%) vs. 2/17 (12%) (p=0.014); CCNA1 11/19 (58%) vs. 4/17 (23.5%) (p=0.048); NID2 13/19 (68%) vs. 3/17 (18%) (p=0.003) and CALCA 10/19 (53%) vs. 4/17 (23.5%) (p=0.097), respectively. We further analyzed PM of CCND2, CCNA1, and CALCA in urine DNA from UCC patients including LGPUCC and controls. The frequency of CCND2, CCNA1 and CALCA was significantly higher (p<0.0001) in urine of UCC cases [ 38/148 (26%), 50/73 (68%) and 94/148 (63.5%) respectively] than controls [0/56 (0%), 10/60 (17%) and 16/56 (28.5%), respectively)]. Most importantly we found any one of the 3 markers methylation positive in 25 out of 30 (83%) cytology negative LGPUCC cases. We also explored the biological function of CCNA1 in UCC. Prospective confirmatory studies are needed to develop a reliable tool for prediction of recurrence using primary LGPUCC tissues and/or urine.

摘要

通过候选基因方法,我们采用定量甲基化特异性PCR(QMSP)分析了17例非复发性和19例复发性非侵袭性低级别乳头状尿路上皮细胞癌(LGPUCC)存档组织DNA中8个基因(ARF、TIMP3、RAR-β2、NID2、CCNA1、AIM1、CALCA和CCND2)的启动子甲基化(PM)情况。在所检测的基因中,通过设定一个经验性临界值,发现CCND2、CCNA1、NID2和CALCA在复发性LGPUCC中的甲基化频率高于非复发性LGPUCC:CCND2为10/19(53%)对2/17(12%)(p = 0.014);CCNA1为11/19(58%)对4/17(23.5%)(p = 0.048);NID2为13/19(68%)对3/17(18%)(p = 0.003);CALCA为10/19(53%)对4/17(23.5%)(p = 0.097)。我们进一步分析了CCND2、CCNA1和CALCA在包括LGPUCC患者和对照者的尿DNA中的PM情况。UCC病例尿液中CCND2、CCNA1和CALCA的频率显著更高(p < 0.0001)[分别为38/148(26%)、50/73(68%)和94/148(63.5%)],而对照者尿液中分别为0/56(0%)、10/60(17%)和16/56(28.5%)。最重要的是,我们发现在30例细胞学检查阴性的LGPUCC病例中有25例(83%)这3种标志物中的任何一种甲基化呈阳性。我们还探究了CCNA1在UCC中的生物学功能。需要进行前瞻性验证研究,以开发一种利用原发性LGPUCC组织和/或尿液来预测复发的可靠工具。

相似文献

1
An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine.一种用于预测低级别乳头状尿路上皮癌(LGPUCC)复发风险的表观遗传标志物组合及其在经尿道切除术后使用尿液进行监测的潜在用途。
Oncotarget. 2014 Jul 30;5(14):5218-33. doi: 10.18632/oncotarget.2129.
2
Epigenetic inactivation of VGF associated with Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine.与尿路上皮细胞癌相关的VGF基因的表观遗传失活及其作为尿液非侵入性生物标志物的潜力。
Oncotarget. 2014 May 30;5(10):3350-61. doi: 10.18632/oncotarget.1949.
3
A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade.一种基于无创尿液的甲基化生物标志物组合,用于检测膀胱癌并区分癌症分级。
Urol Oncol. 2020 Jun;38(6):603.e1-603.e7. doi: 10.1016/j.urolonc.2020.01.007. Epub 2020 Feb 18.
4
Urine cell-based DNA methylation classifier for monitoring bladder cancer.基于尿液细胞的 DNA 甲基化分类器用于膀胱癌监测。
Clin Epigenetics. 2018 May 30;10:71. doi: 10.1186/s13148-018-0496-x. eCollection 2018.
5
A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence.尿沉渣中三个标记物的高甲基化和低甲基化 panel 准确预测膀胱癌复发。
Clin Cancer Res. 2014 Apr 1;20(7):1978-89. doi: 10.1158/1078-0432.CCR-13-2637.
6
Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine.通过检测尿液中的体细胞TERT启动子突变对膀胱癌复发进行无创预测。
Br J Cancer. 2017 Aug 8;117(4):583-587. doi: 10.1038/bjc.2017.210. Epub 2017 Jul 6.
7
Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study.一项多中心研究中用于监测复发性尿路上皮癌的多基因尿液生物标志物检测的性能特征
J Urol. 2017 Jun;197(6):1419-1426. doi: 10.1016/j.juro.2016.12.010. Epub 2016 Dec 14.
8
TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.TERT 启动子突变发生于尿路上皮肿瘤早期,是尿液中早期疾病和疾病复发的生物标志物。
Cancer Res. 2013 Dec 15;73(24):7162-7. doi: 10.1158/0008-5472.CAN-13-2498. Epub 2013 Oct 11.
9
Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer.膀胱癌发病过程中多个基因的异常启动子甲基化。
Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2786-94. doi: 10.1158/1055-9965.EPI-08-0192.
10
Validation of methylation markers for diagnosis of oral cavity cancer.用于口腔癌诊断的甲基化标志物的验证
Eur J Cancer. 2015 Mar;51(5):632-41. doi: 10.1016/j.ejca.2015.01.060. Epub 2015 Feb 13.

引用本文的文献

1
DNA Methylation in Urine and Feces Indicative of Eight Major Human Cancer Types Globally.尿液和粪便中的DNA甲基化可指示全球八大主要人类癌症类型。
Life (Basel). 2025 Mar 17;15(3):482. doi: 10.3390/life15030482.
2
Cell-Free Carbonic Anhydrase IX mRNA in Urine as Biomarker for Urogenital Cancers: The Relationship Between Urinary Extracellular RNA and Tumor-Cell-Associated RNA.尿液中无细胞碳酸酐酶IX信使核糖核酸作为泌尿生殖系统癌症的生物标志物:尿细胞外RNA与肿瘤细胞相关RNA的关系
Curr Issues Mol Biol. 2024 Dec 6;46(12):13881-13892. doi: 10.3390/cimb46120829.
3
Impact of tissue inhibitor of metalloproteinases-3 genetic variants on clinicopathological characteristics of urothelial cell carcinoma.

本文引用的文献

1
Epigenetic inactivation of VGF associated with Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine.与尿路上皮细胞癌相关的VGF基因的表观遗传失活及其作为尿液非侵入性生物标志物的潜力。
Oncotarget. 2014 May 30;5(10):3350-61. doi: 10.18632/oncotarget.1949.
2
Cancer statistics, 2014.癌症统计数据,2014 年。
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7.
3
Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers.
金属蛋白酶组织抑制剂-3基因变异对尿路上皮细胞癌临床病理特征的影响
J Cancer. 2023 Jan 22;14(3):360-366. doi: 10.7150/jca.81083. eCollection 2023.
4
Predicting Recurrence of Non-Muscle-Invasive Bladder Cancer: Current Techniques and Future Trends.预测非肌层浸润性膀胱癌的复发:当前技术与未来趋势
Cancers (Basel). 2022 Oct 14;14(20):5019. doi: 10.3390/cancers14205019.
5
The prognostic role of steroid hormone receptor signaling pathways in urothelial carcinoma.类固醇激素受体信号通路在上皮性膀胱癌中的预后作用。
Transl Cancer Res. 2020 Oct;9(10):6596-6608. doi: 10.21037/tcr.2020.01.06.
6
Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?尿路上皮膀胱癌尿液生物标志物发现的趋势:DNA、RNA还是蛋白质?
Transl Androl Urol. 2021 Jun;10(6):2787-2808. doi: 10.21037/tau-20-1327.
7
Noninvasive Urine-Based Tests to Diagnose or Detect Recurrence of Bladder Cancer.用于诊断或检测膀胱癌复发的非侵入性尿液检测
Cancers (Basel). 2021 Apr 1;13(7):1650. doi: 10.3390/cancers13071650.
8
DNA-Methylation-Based Detection of Urological Cancer in Urine: Overview of Biomarkers and Considerations on Biomarker Design, Source of DNA, and Detection Technologies.基于 DNA 甲基化的尿液泌尿系统癌症检测:生物标志物概述及对生物标志物设计、DNA 来源和检测技术的考虑。
Int J Mol Sci. 2019 May 30;20(11):2657. doi: 10.3390/ijms20112657.
9
An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer.用于非肌肉浸润性膀胱癌监测的现有尿生物标志物的最新目录。
World J Urol. 2018 Dec;36(12):1981-1995. doi: 10.1007/s00345-018-2380-x. Epub 2018 Jun 21.
10
Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus.识别用于 Barrett 食管非内镜检测的 DNA 甲基化生物标志物。
Sci Transl Med. 2018 Jan 17;10(424). doi: 10.1126/scitranslmed.aao5848.
吸烟者与从不吸烟者肺腺癌中表观遗传沉默基因的全基因组揭示
Carcinogenesis. 2014 Jun;35(6):1248-57. doi: 10.1093/carcin/bgt494. Epub 2014 Jan 7.
4
TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.TERT 启动子突变发生于尿路上皮肿瘤早期,是尿液中早期疾病和疾病复发的生物标志物。
Cancer Res. 2013 Dec 15;73(24):7162-7. doi: 10.1158/0008-5472.CAN-13-2498. Epub 2013 Oct 11.
5
Multivalent pseudopeptides targeting cell surface nucleoproteins inhibit cancer cell invasion through tissue inhibitor of metalloproteinases 3 (TIMP-3) release.多价假肽靶向细胞表面核蛋白通过释放金属蛋白酶组织抑制剂 3(TIMP-3)抑制癌细胞侵袭。
J Biol Chem. 2012 Dec 21;287(52):43685-93. doi: 10.1074/jbc.M112.380402. Epub 2012 Oct 29.
6
Absence of the basement membrane component nidogen 2, but not of nidogen 1, results in increased lung metastasis in mice.基底膜成分缺失 2 型巢蛋白(nidogen 2)而非 1 型巢蛋白(nidogen 1)会导致小鼠肺部转移增加。
J Histochem Cytochem. 2012 Apr;60(4):280-9. doi: 10.1369/0022155412436586. Epub 2012 Jan 19.
7
Cancer epigenetics: above and beyond.癌症表观遗传学:超越传统认识。
Toxicol Mech Methods. 2011 May;21(4):275-88. doi: 10.3109/15376516.2011.562671.
8
Integrated genetic and epigenetic analysis identifies haplotype-specific methylation in the FTO type 2 diabetes and obesity susceptibility locus.整合遗传和表观遗传分析鉴定 FTO 型 2 型糖尿病和肥胖易感性位点的单倍型特异性甲基化。
PLoS One. 2010 Nov 18;5(11):e14040. doi: 10.1371/journal.pone.0014040.
9
Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.膀胱癌的综合遗传和表观遗传分析显示 FGFR3 突变和超甲基化事件具有附加的诊断价值。
Int J Cancer. 2011 Jul 1;129(1):78-87. doi: 10.1002/ijc.25651. Epub 2010 Nov 3.
10
Epigenomics and ovarian carcinoma.表观基因组学与卵巢癌。
Biomark Med. 2010 Aug;4(4):543-70. doi: 10.2217/bmm.10.72.